Gilead Sciences GILD Rest of World — Total revenues
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's rest of world — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's rest of world — total revenues?
- Gilead Sciences (GILD) reported rest of world — total revenues of $889M in Q1 2026.
- How has Gilead Sciences's rest of world — total revenues changed year-over-year?
- Gilead Sciences's rest of world — total revenues decreased by 2.8% year-over-year, from $915M to $889M.
- What is the long-term trend for Gilead Sciences's rest of world — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's rest of world — total revenues has grown at a -3.7% compound annual growth rate (CAGR), from $3.93B to $3.5B.
- What does rest of world — total revenues mean?
- Total revenue generated from sales in geographic regions outside of the company's primary markets.
- How do you interpret rest of world — total revenues?
- An increase indicates successful market expansion or higher demand for therapies in international territories, while a decrease may signal competitive pressure, regulatory hurdles, or pricing challenges in those regions.
- How does rest of world — total revenues compare across companies?
- Peers typically report this as 'International Revenue' or 'Rest of World' segment revenue, often excluding major markets like the U.S., Europe, or Japan depending on the company's specific reporting structure.